Compare Cassava Sciences Inc (FLNA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs DENTSPLY SIRONA Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.73B). The key difference: DENTSPLY SIRONA Inc is far larger — about 43.9× Cassava Sciences Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| FLNA | XRAY | |
|---|---|---|
Market Cap | $39.40M | $1.73B |
Volume | 759,018 | 6,198,582 |
Sector | Health | Health |
52-Week High | $4.64 | $14.68 |
52-Week Low | $0.68 | $8.52 |
Typical Hold Time | 37 Days | 72 Days |
Enterprise Value | -$43.28M | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
DENTSPLY SIRONA (XRAY) trades at $8.54, near a 52-week low, with a bearish technical signal from moving averages. The company reported a Q2 2026 earnings beat but faces declining revenues and negative net income margins. Recent news highlights institutional stake increases and ongoing turnaround efforts amid sales weakness in dental segments.
The outlook remains challenging due to persistent profitability issues and high debt, though analyst consensus suggests upside to a $13.40 price target. Key risks include margin pressure and competitive threats, while potential catalysts include successful restructuring and digital dentistry growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
